Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects
NCT07500181Phase 1Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAL2420 in Gram-negative bacterial infection (3 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Adverse Events at Day 10 and Abnormal Electrocardiogram QT Interval at Day 10. Started Mar 2026; status: recruiting.
02
Drugs
BAL2420
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT07500181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07500181.